<DOC>
	<DOCNO>NCT01709110</DOCNO>
	<brief_summary>The primary purpose participation study answer whether teriparatide superior risedronate reduce occurrence new vertebral fracture 24 month therapy .</brief_summary>
	<brief_title>VERtebral Fracture Treatment Comparisons Osteoporotic Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Spinal Fractures</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Postmenopausal woman osteoporosis , define low bone mineral density ( BMD ) , i.e . anteriorposterior lumbar spine , total hip femoral neck BMD â‰¥1.5 standard deviation average BMD young , healthy , nonHispanic , Caucasian woman A minimum 2 moderate 1 severe vertebral fragility fracture ( confirmed central reader ) require Increased risk osteosarcoma History unresolved skeletal disease affect bone metabolism History atypical subtrochanteric diaphyseal femoral fracture Abnormally high low calcium level Abnormally high parathyroid hormone ( PTH ) level Severe vitamin D deficiency Abnormal thyroid function correct therapy History malignant neoplasms last 5 year Active liver disease , clinical jaundice Significant impairment hepatic renal function History nephro urolithiasis Previous plan kypho vertebroplasty Active risk osteonecrosis jaw Active recent history upper gastrointestinal disorder Unable stand sit upright position least 30 minute</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Bone Loss</keyword>
	<keyword>Vertebral fracture</keyword>
</DOC>